AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24633366 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 2)
Number of subjects: 7263
Study 24633366 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (batch 3)
Number of subjects: 7263
Study 24633366 — intervention group
Group type: COMPARATOR
Intervention: EV71 vaccine
Number of subjects: 7263
Study 24633366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7263
Study 22427749 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Elective Repeat Caesarean (ERC)
Number of subjects: 2345
Study 22427749 — intervention group
Group type: COMPARATOR
Intervention: Planned Vaginal Birth after Caesarean (VBAC)
Number of subjects: 2345
Study 20374349 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX bone marker feedback (BMF) at 3 months
Number of subjects: 596
Study 20374349 — intervention group
Group type: COMPARATOR
Intervention: No BMF
Number of subjects: 596
Study 20374349 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX BMF
Number of subjects: 596
Study 18232240 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic, psychosocial engagement strategy (ethnographic and motivational interviewing)
Number of subjects: 0
Study 16039195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin treatment (short-acting insulin 1 IU.kg(‐1).h(‐1) with 30% glucose 1.5 mL.kg(‐1).h(‐1))
Number of subjects: 40
Study 16039195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin treatment
Number of subjects: 40
Study 16039195 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (saline)
Number of subjects: 40
Study 12039085 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed about the VOKS results (report group)
Number of subjects: 0
Study 12039085 — intervention group
Group type: COMPARATOR
Intervention: Not informed about the VOKS results (control group)
Number of subjects: 0
Study 9808873 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 41
Study 9808873 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (100 mg)
Number of subjects: 41
Study 9808873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg i.v. prior to thrombolytic therapy and 325 mg/day orally)
Number of subjects: 41
Study 9808873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 41
Study 7655770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulpiride (2 x 50 mg capsules, 200 mg tablets)
Number of subjects: 12
Study 7655770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sulpiride (100 mg)
Number of subjects: 12
Study 7655770 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on 2 Weibull-functions
Number of subjects: 12
Study 2070512 — intervention group
Group type: EXPERIMENTAL
Intervention: Telelab Personal Blood Pressure Transmitter
Number of subjects: 92
Study 2070512 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometers
Number of subjects: 92
Study 6311774 — intervention group
Group type: EXPERIMENTAL
Intervention: bolus 6-methylprednisolone (B/6-MP)
Number of subjects: 30
Study 6311774 — intervention group
Group type: COMPARATOR
Intervention: corticotrophin (ACTH)
Number of subjects: 30
Study 31065111 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on day 1 and day 8)
Number of subjects: 309
Study 31065111 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (850, 1000, or 1200 mg/m² intravenously every 21 days)
Number of subjects: 309
Study 31065111 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 309
Study 31065111 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 309
Study 29797389 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 29797389 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy (BBT)
Number of subjects: 0
Study 27333022 — intervention group
Group type: EXPERIMENTAL
Intervention: High total serum IgG levels
Number of subjects: 1367
Study 27333022 — intervention group
Group type: EXPERIMENTAL
Intervention: High total serum IgM levels
Number of subjects: 1367
Study 27333022 — intervention group
Group type: COMPARATOR
Intervention: Basic risk model
Number of subjects: 1367
Study 25103909 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Number of subjects: 151
Study 25103909 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 151
Study 25103909 — intervention group
Group type: COMPARATOR
Intervention: Waiting control (WC)
Number of subjects: 151
Study 23095799 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg/day)
Number of subjects: 95
Study 23095799 — intervention group
Group type: COMPARATOR
Intervention: ARB (doubled dose)
Number of subjects: 95
Study 23095799 — intervention group
Group type: COMPARATOR
Intervention: CCB (doubled dose)
Number of subjects: 95
Study 19252451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g SCE‐A cream (n = 150)
Number of subjects: 305
Study 19252451 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n = 155)
Number of subjects: 305
Study 17681970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg kg(‐1) i.v. 5 min before induction of general anaesthesia
Number of subjects: 17
Study 17681970 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 5 min before induction of anaesthesia
Number of subjects: 17
Study 16402012 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson's Baby products used daily for 8 weeks
Number of subjects: 606
Study 16402012 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson's Baby products used daily for 8 weeks in 186 newborns (92 female plus 94 male) aged 0-4 weeks
Number of subjects: 606
Study 11978464 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC-lidocaine mixture (n = 35)
Number of subjects: 70
Study 11978464 — intervention group
Group type: COMPARATOR
Intervention: Pure HPMC 2.25% (n = 35)
Number of subjects: 70
Study 9795882 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study 9795882 — intervention group
Group type: EXPERIMENTAL
Intervention: Models for relaxing assumptions regarding covariate and statistical submodels
Number of subjects: 0
Study 8599066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-1-1 schedule (one dose in right arm and one in left arm at day 0, one dose on days 7 and 21)
Number of subjects: 12
Study 8599066 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant schedule (double dose on day zero and another on day 14)
Number of subjects: 12
Study 8599066 — intervention group
Group type: COMPARATOR
Intervention: 3 doses (2-1-1 schedule)
Number of subjects: 12
Study 2807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea-containing cream
Number of subjects: 0
Study 162678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 (bromazepam)
Number of subjects: 25
Study 162678 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 25
Study 162678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 5‐3350 (bromazepam) during pregnancy
Number of subjects: 25
Study 31790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 164
Study 31790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin with MRD-negative status (CR/CRi)
Number of subjects: 164
Study 31790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (MRD-negative patients)
Number of subjects: 164
Study 31006770 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile immunization team visit
Number of subjects: 0
Study 31006770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile immunization team visit)
Number of subjects: 0
Study 31006770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination coverage among all HCWs
Number of subjects: 0
Study 28349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds (5 g daily throughout treatment)
Number of subjects: 80
Study 28349493 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 80
Study 25956072 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol FDC 5/5 μg
Number of subjects: 0
Study 25956072 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 22915784 — intervention group
Group type: EXPERIMENTAL
Intervention: RA(1)
Number of subjects: 10
Study 22915784 — intervention group
Group type: EXPERIMENTAL
Intervention: RA(4)
Number of subjects: 10
Study 22915784 — intervention group
Group type: COMPARATOR
Intervention: RA(2)
Number of subjects: 10
Study 22915784 — intervention group
Group type: COMPARATOR
Intervention: RA(3)
Number of subjects: 10
Study 22915784 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV(2) and PTV(3)
Number of subjects: 10
Study 22915784 — intervention group
Group type: EXPERIMENTAL
Intervention: RA plans (RA(1-4))
Number of subjects: 10
Study 22915784 — intervention group
Group type: EXPERIMENTAL
Intervention: RA(1) and RA(4)
Number of subjects: 10
Study 22915784 — intervention group
Group type: COMPARATOR
Intervention: RA(2) and RA(3)
Number of subjects: 10
Study 21593490 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamins B-6 3 mg, B-12 0.02 mg) and omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids 600 mg)
Number of subjects: 1748
Study 21593490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1748
Study 19912346 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BOTOX), maximum 200 units at baseline and month 3, plus oral placebo
Number of subjects: 60
Study 19912346 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TOPAMAX), 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections
Number of subjects: 60
Study 16978233 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 128
Study 16978233 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 128
Study 12828495 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 961
Study 12828495 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 961
Study 10931368 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) cases
Number of subjects: 28
Study 10931368 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 28
Study 9132744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) dry powder inhaler 2 x 250 micrograms/d
Number of subjects: 169
Study 9132744 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide (FLUN) metered dose inhaler 2 x 500 micrograms/d
Number of subjects: 169
Study 8454015 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial load
Number of subjects: 10
Study 8454015 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic spring load
Number of subjects: 10
Study 8454015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretched-spring load
Number of subjects: 10
Study 3531315 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 2 g 2 i.d. (on waking and at bedtime)
Number of subjects: 77
Study 3531315 — intervention group
Group type: COMPARATOR
Intervention: sucralfate 1 g 4 i.d. (1/2 h before meals and at bedtime)
Number of subjects: 77
Study 29330940 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 39
Study 29330940 — intervention group
Group type: COMPARATOR
Intervention: Intralesional steroid injection
Number of subjects: 39
Study 28391662 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (5% CSPS and sodium fluoride)
Number of subjects: 304
Study 28391662 — intervention group
Group type: COMPARATOR
Intervention: Comparator dentifrice (5% CSPS and sodium monofluorophosphate)
Number of subjects: 304
Study 24211400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 114
Study 24211400 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 114
Study 23164667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral inferior alveolar nerve block (BIANB)
Number of subjects: 30
Study 23164667 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (general anesthesia with postoperative morphine treatment)
Number of subjects: 30
Study 20584355 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study 20584355 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 20584355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (as the least expensive option)
Number of subjects: 0
Study 18563786 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative radiotherapy (PRT)
Number of subjects: 785
Study 18563786 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision (TME) without preoperative radiotherapy (PRT)
Number of subjects: 785
Study 16085588 — intervention group
Group type: EXPERIMENTAL
Intervention: F + 0 protocol (immediate administration of radiopharmaceutical after furosemide)
Number of subjects: 108
Study 16085588 — intervention group
Group type: COMPARATOR
Intervention: F - 15 protocol (radiopharmaceutical administered 15 min after furosemide)
Number of subjects: 108
Study 16085588 — intervention group
Group type: COMPARATOR
Intervention: F - 15 protocol
Number of subjects: 108
Study 16085588 — intervention group
Group type: EXPERIMENTAL
Intervention: F + 0 protocol
Number of subjects: 108
Study 12166604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program of weight loss, improvement of diet, increase of physical exercise and smoking cessation
Number of subjects: 0
Study 12166604 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 12166604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10614061 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 1-17 stimulation test
Number of subjects: 30
Study 10614061 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 30
Study 7546992 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50-100 mg twice daily
Number of subjects: 210
Study 7546992 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 100-200 mg twice daily
Number of subjects: 210
Study 7546992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoprolol and xamoterol
Number of subjects: 210
Study 7546992 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 210
Study 1741985 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interviews by a perioperative nurse
Number of subjects: 60
Study 1741985 — intervention group
Group type: COMPARATOR
Intervention: No preoperative interviews (control group)
Number of subjects: 60
Study 6920252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/dose) administered 72, 48, and 24 hours before delivery
Number of subjects: 24
Study 6920252 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 24
Study 6920252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg/dose)
Number of subjects: 24
Study 31652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming intervention (once‐weekly 50‐minute sessions during recess for 8 months)
Number of subjects: 81
Study 31652857 — intervention group
Group type: COMPARATOR
Intervention: Regular recess (control group)
Number of subjects: 81
Study 31652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming intervention
Number of subjects: 81
Study 28910200 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-g β-alanine (12G)
Number of subjects: 30
Study 28910200 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-g β-alanine (6G)
Number of subjects: 30
Study 28910200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30
Study 25695900 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to online educational modules
Number of subjects: 37
Study 25695900 — intervention group
Group type: COMPARATOR
Intervention: No access to online educational modules
Number of subjects: 37
Study 23494053 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated heparin (UFH)
Number of subjects: 43
Study 23494053 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 IU low-molecular-weight heparin (LMWH, dalteparin)
Number of subjects: 43
Study 23494053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both heparin types
Number of subjects: 43
Study 21436709 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site training for nurse-midwives in intervention sites
Number of subjects: 2444
Study 19565734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with magnetic therapy
Number of subjects: 82
Study 19565734 — intervention group
Group type: COMPARATOR
Intervention: Simple magnetic therapy (Control)
Number of subjects: 82
Study 18006969 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsies for participants with a prostate specific antigen level of 1.5 ng/ml or more
Number of subjects: 1299
Study 15994145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d orally)
Number of subjects: 420
Study 15994145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tamoxifen)
Number of subjects: 420
Study 15994145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 420
Study 11937566 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BIRB 796 BS
Number of subjects: 24
Study 11937566 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BIRB 796 BS
Number of subjects: 24
Study 11937566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9704781 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine, 0.25%, 13 mL
Number of subjects: 305
Study 9704781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil, 10 microg
Number of subjects: 305
Study 9704781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil
Number of subjects: 305
Study 9704781 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 305
Study 9704781 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia in the left lateral position
Number of subjects: 305
Study 8582463 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate 10 mg
Number of subjects: 12
Study 8582463 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate 15 mg
Number of subjects: 12
Study 8582463 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1 mg (positive control)
Number of subjects: 12
Study 8582463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2371073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube placement in infants <2 kg
Number of subjects: 39
Study 2371073 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube placement in infants <2 kg
Number of subjects: 39
Study 2371073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube placement in infants >2 kg
Number of subjects: 39
Study 2371073 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube placement in infants >2 kg
Number of subjects: 39
Study 2371073 — intervention group
Group type: COMPARATOR
Intervention: No gastric intubation
Number of subjects: 39
Study 350248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (fast injection)
Number of subjects: 0
Study 350248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (slow injection)
Number of subjects: 0
Study 350248 — intervention group
Group type: COMPARATOR
Intervention: Other vasodilator hypotensive drugs
Number of subjects: 0
Study 31593271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-initiated program combining transitional care and long-term self-management support (n=120)
Number of subjects: 240
Study 31593271 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=120)
Number of subjects: 240
Study 27310606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation therapy (6 sessions of 30 minutes each)
Number of subjects: 60
Study 27310606 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study 26362099 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 899
Study 24111365 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed home-based electrical muscle stimulation training (30 sessions, 1 hour each over 6 weeks)
Number of subjects: 16
Study 20417976 — intervention group
Group type: EXPERIMENTAL
Intervention: Auro®
Number of subjects: 38
Study 20417976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerumol®
Number of subjects: 38
Study 20417976 — intervention group
Group type: EXPERIMENTAL
Intervention: CleanEars®
Number of subjects: 38
Study 18821171 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic echoendoscope
Number of subjects: 80
Study 18821171 — intervention group
Group type: COMPARATOR
Intervention: Mechanical echoendoscope
Number of subjects: 80
Study 17910329 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant 16-kDa protein (r16-kDa)
Number of subjects: 38
Study 17910329 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 38
Study 17910329 — intervention group
Group type: COMPARATOR
Intervention: r16-kDa enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 38
Study 17910329 — intervention group
Group type: COMPARATOR
Intervention: ImmunoCAP (serum IgE measurement)
Number of subjects: 38
Study 15583582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Polypodium leucotomos (PL) 7.5 mg/kg
Number of subjects: 9
Study 11718591 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored smoking cessation program
Number of subjects: 2934
Study 11718591 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 2934
Study 9164223 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1,250 mg/m2 as a 30‐minute intravenous infusion on days 1, 8, and 15 of each 28‐day cycle
Number of subjects: 53